Seronegative antibody‐mediated neurology after immune checkpoint inhibitors

Seronegative antibody‐mediated neurology after immune checkpoint inhibitors

Checkpoint inhibitor medications have revolutionized oncology practice, but frequently induce immune‐related adverse events. During autoimmune neurology practice over 20 months, we prospectively identified four patients with likely antibody‐mediated neurological diseases after checkpoint inhibitors:...

Full description

Bibliographic Details
Main Authors:	Wilson, R, Menassa, D, Davies, A, Michael, S, Hester, J, Kuker, W, Collins, G, Cossins, J, Beeson, D, Steven, N, Maddison, P, Rinaldi, S, Jacob, S, Irani, S
Format:	Journal article
Published:	Wiley 2018

Similar Items

Antibodies to AChRs in seronegative myasthenia gravis
by: Leite, M, et al.
Published: (2006)

IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis.
by: Leite, M, et al.
Published: (2008)

Antibodies to clustered acetylcholine receptor and thymic changes in seronegative myasthenia gravis
by: Leite, M, et al.
Published: (2007)

IgG subclasses of disease-specific antibodies and complement activation in-vitro in seronegative myasthenia gravis and neuromyelitis optica
by: Jacob, S, et al.
Published: (2008)

Myasthenia gravis seronegative for acetylcholine receptor antibodies.
by: Vincent, A, et al.
Published: (2008)

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis.
by: McConville, J, et al.
Published: (2004)

Detection of musk antibodies in seronegative myasthenia gravis using human musk as antigen
by: McConville, J, et al.
Published: (2002)

CLINICAL FEATURES AND FOLLOW-UP OF 13 PATIENTS WITH ANTIBODIES AGAINST NMDA RECEPTORS
by: Irani, SR, et al.
Published: (2009)

A review of neurological complications of immune-checkpoint inhibitors
by: D. Valančius, et al.
Published: (2021-12-01)

SERONEGATIVE MYASTHENIA GRAVIS-CLINICAL/SEROLOGICAL ASPECTS
by: Huda, S, et al.
Published: (2014)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab.
by: Kitley, J, et al.
Published: (2014)

Catastrophic brain relapse in seronegative NMO after a single dose of natalizumab
by: Kitley, J, et al.
Published: (2014)

Antibody-associated autoimmune neurological disease
by: Varley, J, et al.
Published: (2016)

Clinical aspects of MuSK antibody positive seronegative MG.
by: Sanders, D, et al.
Published: (2003)

MuSK antibody-positive, seronegative myasthenia gravis in Korea.
by: Lee, J, et al.
Published: (2006)

Antibodies affecting ion channel function in acquired neuromyotonia, in seropositive and seronegative myasthenia gravis, and in antibody-mediated arthrogryposis multiplex congenita.
by: Vincent, A, et al.
Published: (1998)

Immunoadsorption and plasma exchange in seropositive and seronegative immune-mediated neuropathies
by: Davies, A, et al.
Published: (2020)

Clinical characteristics of anti-neuronal antibody positive paraneoplastic neurological syndrome related to immune checkpoint inhibitors
by: ZHANG Le, et al.
Published: (2024-05-01)

Seronegative generalised myasthenia gravis: clinical features, antibodies, and their targets.
by: Vincent, A, et al.
Published: (2003)

THE UTILITY OF SOX ANTIBODIES FOR CANCER PREDICTION IN PATIENTS WITH PARANEOPLASTIC NEUROLOGICAL DISORDERS
by: Maddison, P, et al.
Published: (2012)

Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study
by: Douglas B. Johnson, et al.
Published: (2019-05-01)

IgG subclasses of disease-specific antibodies and complement activation in vitro in myasthenia gravis and neuromyelitis optica
by: Jacob, S, et al.
Published: (2007)

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders
by: Maddison, P, et al.
Published: (2018)

Neurological Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors
by: Sotiria Stavropoulou De Lorenzo, et al.
Published: (2024-06-01)

Anti-MuSK antibodies in seronegative myasthenia gravis: a cause of denervation
by: Newsom-Davis, J, et al.
Published: (2001)

Seronegative myasthenia gravis.
by: Vincent, A, et al.
Published: (2004)

Inhibition of acetylcholine receptor function by seronegative myasthenia gravis non-IgG factor correlates with desensitisation.
by: Spreadbury, I, et al.
Published: (2005)

Neurological Adverse Events Related to Immune Checkpoint Inhibitors: A Practical Review
by: François Zammit, et al.
Published: (2024-04-01)

Recurrent Cerebral Artery Dissection Associated with Seronegative Antiphospholipid Antibody Syndrome
by: Hee Sue Kim, et al.
Published: (2022-03-01)

Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors
by: Andrew L Mammen, et al.
Published: (2021-07-01)

Remitting seronegative symmetrical synovitis with pitting edema and polymyalgia-like syndromes following cancer immunotherapy with checkpoint inhibitors: causal link, potential association or else?
by: Ciro Manzo
Published: (2021-09-01)

Myasthenia gravis seronegative for acetylcholine receptor antibodies in South Korea: Autoantibody profiles and clinical features
by: Park, K, et al.
Published: (2018)

A rare c.183_187dupCTCAC mutation of the acetylcholine receptor CHRNE gene in a South Asian female with congenital myasthenic syndrome: a case report
by: Chang, T, et al.
Published: (2016)

Low frequency of MuSK antibody in generalized seronegative myasthenia gravis among Chinese.
by: Yeh, J, et al.
Published: (2004)

Effect of sera from AChR-antibody negative myasthenia gravis patients on AChR and MuSK in cell cultures.
by: Farrugia, M, et al.
Published: (2007)

Antibodies identified by cell-based assays in myasthenia gravis and associated diseases.
by: Vincent, A, et al.
Published: (2012)

Seronegative autoimmune hepatitis
by: A. O. Buyeverov
Published: (2018-08-01)

Reappearance of HIV antibody in an infected, seronegative individual after treatment with highly active antiretroviral therapy.
by: Rice, P, et al.
Published: (1999)

Checkpoint Inhibitors and Hepatotoxicity
by: Stephen D. H. Malnick, et al.
Published: (2021-01-01)

Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
by: Josée Golay, et al.
Published: (2020-05-01)